Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
33
CZMWY Quote, Financials, Valuation and Earnings
Last price:
$47.06
Seasonality move
:
8.14%
Day range:
$46.86 - $47.44
52-week range:
$45.96 - $76.28
Dividend yield:
1.37%
P/E ratio:
26.25x
P/S ratio:
1.67x
P/B ratio:
4.60x
Volume:
2.6K
Avg. volume:
3K
1-year change:
-8.23%
Market cap:
$4.1B
Revenue:
$2.5B
EPS (TTM):
$1.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
-- | -- | -- | -- | -- |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.04% | -86.85% | $138.33 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
EVO
Evotec SE
|
$219.8M | -$0.01 | 17.8% | -75.1% | $5.4436 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.87% | -704.25% | $18.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
$47.07 | -- | $4.1B | 26.25x | $0.65 | 1.37% | 1.67x |
|
BNTX
BioNTech SE
|
$92.23 | $138.33 | $22.2B | 191.55x | $0.00 | 0% | 6.27x |
|
CVAC
CureVac NV
|
$4.82 | $5.31 | $1.1B | 6.75x | $0.00 | 0% | 13.39x |
|
EVO
Evotec SE
|
$3.0100 | $5.4436 | $1.1B | -- | $0.00 | 0% | 1.28x |
|
IFRX
InflaRx NV
|
$1.04 | $11.24 | $70.5M | -- | $0.00 | 0% | 321.34x |
|
IMTX
Immatics NV
|
$10.09 | $18.75 | $1.2B | 42.21x | $0.00 | 0% | 13.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
-- | 0.212 | -- | 1.10x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
EVO
Evotec SE
|
37.72% | 1.505 | 44.12% | 1.05x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
$328.5M | $60.2M | 7.37% | 7.44% | 8.67% | $108.3M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
EVO
Evotec SE
|
-$72.4K | -$59.7M | -11.62% | -17.7% | -31.17% | -$101.3M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Carl Zeiss Meditec AG vs. Competitors
-
Which has Higher Returns CZMWY or BNTX?
BioNTech SE has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -1.89%. Carl Zeiss Meditec AG's return on equity of 7.44% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About CZMWY or BNTX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $138.33 which suggests that it could grow by 49.99%. Given that BioNTech SE has higher upside potential than Carl Zeiss Meditec AG, analysts believe BioNTech SE is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 BNTXBioNTech SE14 5 0 -
Is CZMWY or BNTX More Risky?
Carl Zeiss Meditec AG has a beta of 1.587, which suggesting that the stock is 58.713% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock CZMWY or BNTX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.37%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or BNTX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are smaller than BioNTech SE quarterly revenues of $1.8B. Carl Zeiss Meditec AG's net income of $32.2M is higher than BioNTech SE's net income of -$33.5M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 26.25x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.67x versus 6.27x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.67x 26.25x $623.3M $32.2M BNTXBioNTech SE6.27x 191.55x $1.8B -$33.5M
-
Which has Higher Returns CZMWY or CVAC?
CureVac NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -5832.47%. Carl Zeiss Meditec AG's return on equity of 7.44% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About CZMWY or CVAC?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 10.44%. Given that CureVac NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe CureVac NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 CVACCureVac NV1 3 0 -
Is CZMWY or CVAC More Risky?
Carl Zeiss Meditec AG has a beta of 1.587, which suggesting that the stock is 58.713% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock CZMWY or CVAC?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.37%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or CVAC?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than CureVac NV quarterly revenues of $63.3M. Carl Zeiss Meditec AG's net income of $32.2M is lower than CureVac NV's net income of $319.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 26.25x while CureVac NV's PE ratio is 6.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.67x versus 13.39x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.67x 26.25x $623.3M $32.2M CVACCureVac NV13.39x 6.75x $63.3M $319.3M
-
Which has Higher Returns CZMWY or EVO?
Evotec SE has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -26.29%. Carl Zeiss Meditec AG's return on equity of 7.44% beat Evotec SE's return on equity of -17.7%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B EVOEvotec SE-0.04% -$0.14 $1.5B -
What do Analysts Say About CZMWY or EVO?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 81.54%. Given that Evotec SE has higher upside potential than Carl Zeiss Meditec AG, analysts believe Evotec SE is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 EVOEvotec SE1 0 0 -
Is CZMWY or EVO More Risky?
Carl Zeiss Meditec AG has a beta of 1.587, which suggesting that the stock is 58.713% more volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.
-
Which is a Better Dividend Stock CZMWY or EVO?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.37%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or EVO?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than Evotec SE quarterly revenues of $191.5M. Carl Zeiss Meditec AG's net income of $32.2M is higher than Evotec SE's net income of -$50.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 26.25x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.67x versus 1.28x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.67x 26.25x $623.3M $32.2M EVOEvotec SE1.28x -- $191.5M -$50.3M
-
Which has Higher Returns CZMWY or IFRX?
InflaRx NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -51538.49%. Carl Zeiss Meditec AG's return on equity of 7.44% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About CZMWY or IFRX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 981.13%. Given that InflaRx NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe InflaRx NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 IFRXInflaRx NV5 2 0 -
Is CZMWY or IFRX More Risky?
Carl Zeiss Meditec AG has a beta of 1.587, which suggesting that the stock is 58.713% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock CZMWY or IFRX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.37%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or IFRX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than InflaRx NV quarterly revenues of $27.8K. Carl Zeiss Meditec AG's net income of $32.2M is higher than InflaRx NV's net income of -$14.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 26.25x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.67x versus 321.34x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.67x 26.25x $623.3M $32.2M IFRXInflaRx NV321.34x -- $27.8K -$14.3M
-
Which has Higher Returns CZMWY or IMTX?
Immatics NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -974.45%. Carl Zeiss Meditec AG's return on equity of 7.44% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About CZMWY or IMTX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 85.83%. Given that Immatics NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe Immatics NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 IMTXImmatics NV9 0 0 -
Is CZMWY or IMTX More Risky?
Carl Zeiss Meditec AG has a beta of 1.587, which suggesting that the stock is 58.713% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock CZMWY or IMTX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.37%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or IMTX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than Immatics NV quarterly revenues of $6.1M. Carl Zeiss Meditec AG's net income of $32.2M is higher than Immatics NV's net income of -$59.1M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 26.25x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.67x versus 13.48x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.67x 26.25x $623.3M $32.2M IMTXImmatics NV13.48x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
40
HUT alert for Dec 17
Hut 8 Corp. [HUT] is up 12.08% over the past day.
Sell
39
SMX alert for Dec 17
SMX (Security Matters) Plc [SMX] is up 22.55% over the past day.
Sell
45
ZBIO alert for Dec 17
Zenas BioPharma, Inc. [ZBIO] is down 2.33% over the past day.
